Description
Human Serum Albumin (HSA) is made of plasma proteins from human blood, which is mainly used to replace blood volume loss resulting from trauma such as a severe burn or an injury that causes blood loss. It is also used to treat low albumin levels caused by surgery, dialysis, and many other conditions.
Due to the high demand for HSA in the Chinese market, it has become one of the blood products that China allows to import from restricted countries. Currently, there are over 30 manufacturers in the Chinese HSA market. The major manufacturers are Grifols, Baxter, CSL Behring, Aventis Behring, and Shandong Taibang. Among them, Grifols accounts for the largest market share. In 2020, it took about 22.57% of the total market sales.
According to CRI’s market research, the sales revenue of HSA in the Chinese market increased from CNY2.96 billion in 2016 to CNY4.22 billion in 2020. In 2020, the annual growth rate was 11.3%, which slowed down compared to that in 2019 due to the COVID-19 epidemic. The CAGR of sales value of Human Serum Albumin in China is 9.3% in 2016 to 2020. CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of HSA will have a recovery growth from 2021 to 2025.
Topics Covered:
-The impact of COVID-19 on China’s Human Serum Albumin market
– Sales value and volume of China’s Human Serum Albumin 2016-2020
– Competitive landscape of China’s Human Serum Albumin market
– Prices of Human Serum Albumin in China
– Prices of Human Serum Albumin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Human Serum Albumin market
– Prospect of China’s Human Serum Albumin market from 2021 to 2025
